Case Studies - Suzie
Brian T. Barnett, DVM, MBA
Initial Results & Observations: Kush Canine for Treatment of Canine Osteoarthritis.
Randolph Animal Hospital 1435 Zoo Parkway Asheboro, NC 27205 2-18-2016
There is an unmet need to treat canine osteoarthritis (OA) that is safe, affordable, easily administered, efficacious, and without adverse side effects. At Randolph Animal Hospital we see arthritic dogs daily. The canine patient population represents eighty percent of our revenues. Our current treatment for canine OA relies on constant NSAID medication, Opiods (like Tramadol), Gabapentin, anabolic steroids, and Adequan to reduce pain and inflammation. This pharmaceutical therapy has several problems, including limited effect, difficulty in providing consistent compliance (the client must be able to give a pill or injection), and a high likelihood of gastric tract complications.
The Kush Canine particles for intra-articular injection is a medical device designed to prevent the occurrence and reoccurrence of joint pain from loss of cartilage or tissuebone mechanical malfunction caused by joint dysfunction not associated with infection (e.g., lameness, osteoarthritis). The injected Kush particles are micro-sized lubricious cushions that provide an artificial cartilage effect to protect the joint's natural tissue during joint articulation.
The following case study was conducted at Randolph Animal Hospital using client owned dogs treated with Kush Canine:
Case Study #2 “Suzie” Phillips Breed: Golden Retriever Age: 11 years Weight: 60 lbs Condition: Congenital Hip Dysplasia (diagnosed at less than one year of age via radiographs after the puppy presented "bunny hopping")
Treatment: Suzie presented grade 2/3 lameness. She was very reluctant to get up from a lying position and walks "post legged" in her hind quarters. She refuses to jump on the sofa or into a car. She will walk stairs reluctantly. She has used NSAIDS as needed since 2005 but consistently since Nov. 2013.
Radiographs changes show advanced severe degenerative joint changes in both coxofemoral joints and flattening of both femoral heads. Nov. 25, 2015, Suzie was anesthetized employing propofol as an induction agent and maintained on isoflurane and oxygen. The right coxofemoral joint was tapped employing a 20 gauge 2 inch IV cath. 1 cc of joint fluid was withdrawn and 0.5 cc of Vetalog (Triamcinolone) infused followed by 1.2 cc Kush Canine. 0.15 cc of joint fluid were withdrawn from the left coxofemoral joint. 0.5 cc of Triamcinolone followed by 1.2 cc of Kush Canine were infused. Suzie had improvement in her gait and had minimal NSAIDS given until 1-18-2016 at which point she developed a swelling on the right caudal portion of her skull which was diagnosed as Osteosarcoma (this cancer was not associated with Kush Canine. Golden Retrievers have a very high cancer rate genetically) via biopsy. Due to the pain associated with this disease she has been on Deramaxx and Tramadol since.
The Kush canine treatment device is delivered via intraarticular injection. The particles inject easily and smoothly into the synovial space using either a 20 or 22 gauge needle. This is a straightforward in-clinic procedure to preform. We are seeing excellent early results treating knee, hip & elbow joints. Improvement was seen by the next day. The results may have been visible more quickly but the patients all had post op opiod injectable medications. We are seeing increased range of motion. Owners are reporting visibly better ambulation and more ease in raising. Two of the dogs were able to stop NSAIDS completely.
The proposed pricing structure for the product builds a strong business case for our animal hospital and for our clients. The Kush procedure revenues are generated at time of treatment, in the clinic. This is important because veterinary clinics/hospitals are seeing margin and profit eroded, as more and more pharmaceutical prescriptions are being fulfilled outside the clinic rather than at the veterinary clinics/hospitals.
While my experience and observations of the Kush product are limited in duration I believe this product has demonstrated to be effective in treating canine OA joints. This product shows much potential in serving the very large arthritic canine population and growth within my practice.
2014-2016 Brian T. Barnett, DVM, MBA Dr. Barnett has been the owner and chief of staff at Randolph Animal Hospital in Asheboro, NC since May of 2002. Dr. Barnett earned his Bachelors of Science in Zoology from Auburn University and then his Doctorate in Veterinary Medicine from Auburn University's College of Veterinary Medicine. In addition to his science and veterinary degrees, Dr. Barnett holds an MBA from Wake Forest's Babcock School of Management.